Galux signed a research agreement with Boehringer Ingelheim to explore AI‑driven protein design for therapeutic applications. The collaboration will evaluate whether generative and predictive models can deliver ‘purpose‑specific’ protein molecules that meet precise scientific and translational criteria where conventional discovery struggles. Galux brings recent de novo antibody design milestones and claims of high binding affinity, structural precision and stability; Boehringer contributes translational expertise. The initial phase will validate feasibility across selected cases and could expand to broader co‑development if AI‑designed candidates meet preclinical benchmarks. For clarity: AI protein design here refers to algorithmic de novo generation and in silico optimization of amino‑acid sequences for defined functions.